Vernalis Research is based at Granta Park in Cambridge, UK. Here is a brief summary of our evolution and successes.
- Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) acquired Vernalis plc. Vernalis Research now operates as a subsidiary of Ligand Holdings UK Ltd, wholly owned by Ligand Pharmaceuticals, Inc.
- Success milestones achieved under drug discovery collaboration with Daiichi Sankyo on two undisclosed oncology targets
- Achieved third success milestone from drug discovery collaboration with Asahi Kasei Pharma on an undisclosed target for rheumatoid arthritis and other autoimmune diseases
- Achieved 3 milestones in oncology drug discovery collaboration with Servier, including Mcl-1 clinical candidate first time in man, and entered into a fourth research collaboration
- Achieved a clinical milestone from an adenosine A2A receptor antagonist collaboration with Corvus Pharmaceuticals, who announced positive data from a Phase 1/1b study with single agent CPI-444 in patients with renal cell carcinoma
- Entered into research collaboration with Daiichi Sankyo on undisclosed oncology targets
- Achieved research milestone in collaboration with Asahi Kasei Pharma
- V158866, the lead molecule arising from our FAAH internal research programme, completed a phase II study in spinal cord injury patients
- Licensed proprietary adenosine receptor antagonist technology, including lead A2A antagonist V81444 (later CPI-444), for development and commercialisation to Corvus Pharmaceuticals
- Awarded a Queen’s Award for Enterprise in International Trade, endorsing both our talent and capabilities, and recognising achievement in growing overseas earnings through research collaborations
- Licensed worldwide rights in vipadenant, a small molecule A2A receptor antagonist, for use in immuno-oncology to RedoxTherapies (a Celgene company)
- Licenced worldwide rights in tosedostat, an orally active aminopeptidase inhibitor for use in oncology, to CTI BioPharma
- Entered into a drug discovery collaboration with Genentech (now completed) utilising Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target
- Achieved a pre-clinical milestone in the first oncology research collaboration with Servier and entered into a third research collaboration
- Positive results obtained from a Phase I trial of V158866, a FAAH inhibitor with potential application in a wide range of pain and other indications
- Hsp90 inhibitor, NVP-AUY922 achieved clinical proof of concept
- Two milestones from research collaboration with H. Lundbeck A/S on LRRK2 inhibitors obtained
- First research collaboration with Servier (which is still active); growing expertise in biophysical methods such as ITC and SPR
- Research concentrated on Granta Park site with in-house projects on oncology targets
- Series of mergers created Vernalis plc, combining the expertise of RiboTargets with CNS targets and GPCR pharmacology from Vernalis Group in Winnersh, as well as DMPK capability, a clinical pipeline and a marketed product, frovatriptan
- Research changed focus to oncology protein targets; development of the SeeDs fragment-based discovery platform
- Structure-based discovery of inhibitors of the 30S subunit of the ribosome; established X-ray crystallography
- RiboTargets established fragment- and structure-based drug discovery against RNA targets; established macromolecular NMR spectroscopy
We have expertise in the key areas needed to characterise new protein targets, develop assays, identify and validate hits from fragments and other sources, evolve these into lead compounds guided by protein structure, and optimise these further to deliver drug candidates. Our team also has a well-established core of experience; many of us have worked together for over a decade, and this brings breadth and depth to our knowledge pool.
We offer talented and motivated individuals excellent training and development opportunities within our creative, multidisciplinary teams, and a benefits package which includes a competitive salary (in line with qualifications and experience) plus pension, private medical cover and life assurance. By choosing Vernalis Research, you will have the opportunity of working on stimulating, innovative projects in a collaborative environment with other scientists worldwide.
We welcome applications from suitably qualified scientists, researchers and other candidates for the positions listed below. If no vacancies are listed at this time, please check back regularly if you are interested in working with Vernalis, or send your CV and covering letter to firstname.lastname@example.org.
All applicants must be eligible to live and work in the UK.
We operate an equal opportunities employment policy.